5 Changes in Stockholder’s Equity

COMMON STOCK

On 30 September 2014, the Company's common stock amounted to € 26,392,084 (31 December 2013: € 26,220,882).

As of 30 September 2014, the value of treasury stock increased from € 6,418,018 on 31 December 2013 to € 14,251,962 as a result of MorphoSys's repurchase of 111,000 of its own shares on the stock exchange at an average price of € 70.53 per share. The treasury stock may be used for all purposes named in the authorization of the Annual General Meeting on 19 May 2011 and especially for any existing or future employee participation schemes and/ or to finance acquisitions. The shares may also, however, be redeemed.

AUTHORIZED CAPITAL

The number of authorized ordinary shares increased to 4,957,910 compared to 2,335,822 on 31 December 2013. This was the result of new Authorized Capital 2014-I created at the Annual General Meeting on 23 May 2014. With the Supervisory Board's consent, the Management Board is authorized to increase the Company's common stock on one or more occasions by up to € 2,622,088 by issuing up to 2,622,088 new, no-par value bearer shares up to and including the date of 30 April 2019.

CONDITIONAL CAPITAL

The number of ordinary shares of conditional capital decreased to 7,231,598 compared to 8,057,470 on 31 December 2013. At the Annual General Meeting on 23 May 2014, the Conditional Capital 1999-I in the amount of € 70,329 and the Conditional Capital 2008/II in the amount of € 212,077 were cancelled. Conditional Capital 2003-II was reduced by € 372,264 from € 725,064 to € 352,800. A further reduction of Conditional Capital 2003-II of € 171,202 to a total of € 181,598 resulted from the exercise of 171,202 conversion rights during the first nine months of 2014.

ADDITIONAL PAID-IN CAPITAL

On 30 September 2014, additional paid-in capital amounted to € 316,512,505 (31 December 2013: € 310,963,651). The increase of € 5,548,854 arose from exercised conversion rights and from personnel expenses resulting from share-based payments.

REVALUATION RESERVE

On 30 September 2014, the revaluation reserve amounted to € -40,923 (31 December 2013: € 240,381). The decrease of € 281,304 resulted from a change in unrealized gains from available-for-sale securities and bonds.

TRANSLATION RESERVE

During the first nine months of the year, the translation reserve increased by € 101,237 from € 192,556 on 31 December 2013 to € 293,793. This item included exchange differences arising from the revaluation of financial statements carried in foreign currencies by Group companies, as well as differences between the exchange rates used in the balance sheet and those used in the income statement.

Top